Effects of the STING R232/H232 Variant on the Prognosis of Inflammatory Bowel Disease
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Galenos Publishing House
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim: Inflammatory bowel disease (IBD) refers to a group of diseases which cause chronic and recurrent inflammation in different parts of the digestive tract, such as Crohn's disease (CD) or ulcerative colitis (UC). CD can affect both the large and small intestines, while UC usually affects only the large intestine. Recent studies in immunogenetics have revealed that the innate immune system is crucial in triggering gut inflammation, and rare variants in genes which function in this system are important risk factors forthis disease. Stimulatorof interferon genes (STING) is a nucleotide-binding endoplasmic reticulum protein involved in the innate immune response. This study aimed to analyse the R232/ H232 variant in the STING1 gene in pediatric patients diagnosed with IBD and to investigate whether this variant is associated with the prognosis of IBD. Materials and Methods: Thirty-five pediatric patients admitted with a prediagnosis of IBD were included in this study. The R232/H232 variant was determined by end-point genotyping analysis after real-time reverse transcription-polymerase chain reaction (qRT-PCR) reactions using affinity probes. qRT-PCR analyses were performed to determine the mRNA expression levels of STING and interferon-induced genes in tissue samples. The western blotting method determined STING expression at the protein level. Results: It was determined that 31.43% of the patients had heterozygous (R232/H232), and 68.57% had homozygous (H232/H232) genotypes. A significant difference was found between the genotype distribution and treatment stage. It was determined that 87.50% of the patients who started second-stage treatment had homozygous genotypes. It was also found that homozygous patients had longer durations of attacks than heterozygous patients. Conclusion: R232/H232, the most common variant in the STING1 gene, affects treatment response and attack duration in patients with IBD. Therefore, we suggest that variants in the STING1 gene may be used to develop genetic-based personalized treatment strategies for IBD patients in the future.
Açıklama
Anahtar Kelimeler
Crohn’s disease, inflammatory bowel disease, R232/H232, STING, ulcerative colitis
Kaynak
The Journal of Pediatric Research
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
11
Sayı
4
Künye
Akyol, G., Karakoyun, M., Barut, D., Köse, T., & Bozok, V. (2024). Effects of the STING R232/H232 variant on the prognosis of inflammatory bowel disease. The Journal of Pediatric Research, 11(4), 198-206.
